Gabelli Funds LLC bought a new stake in shares of NxStage Medical, Inc. (NASDAQ:NXTM) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 179,013 shares of the medical device company’s stock, valued at approximately $4,941,000. Gabelli Funds LLC owned 0.27% of NxStage Medical as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. CWM LLC acquired a new position in shares of NxStage Medical in the second quarter worth $2,684,000. Birchview Capital LP increased its stake in shares of NxStage Medical by 21.3% in the second quarter. Birchview Capital LP now owns 34,200 shares of the medical device company’s stock worth $857,000 after acquiring an additional 6,000 shares during the last quarter. Redmile Group LLC acquired a new position in shares of NxStage Medical in the second quarter worth $16,480,000. Schwab Charles Investment Management Inc. increased its stake in shares of NxStage Medical by 7.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 277,899 shares of the medical device company’s stock worth $7,457,000 after acquiring an additional 18,189 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of NxStage Medical by 8.5% in the first quarter. Vanguard Group Inc. now owns 5,273,762 shares of the medical device company’s stock worth $141,495,000 after acquiring an additional 412,233 shares during the last quarter. 92.31% of the stock is currently owned by institutional investors.

Shares of NxStage Medical, Inc. (NASDAQ NXTM) opened at $25.79 on Monday. NxStage Medical, Inc. has a fifty-two week low of $20.45 and a fifty-two week high of $30.80.

WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/11/13/gabelli-funds-llc-buys-new-position-in-nxstage-medical-inc-nxtm.html.

In other news, President Joseph E. Turk, Jr. sold 1,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $27.56, for a total transaction of $27,560.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $29.21, for a total transaction of $102,235.00. Following the transaction, the senior vice president now directly owns 16,270 shares of the company’s stock, valued at approximately $475,246.70. The disclosure for this sale can be found here. Insiders have sold 17,600 shares of company stock valued at $496,902 over the last 90 days. Corporate insiders own 4.70% of the company’s stock.

A number of equities analysts have recently weighed in on the stock. William Blair downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, August 7th. Jefferies Group LLC downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating and dropped their price target for the stock from $33.00 to $30.00 in a research note on Tuesday, August 8th. Stephens downgraded shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $33.00 to $30.00 in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a report on Thursday, August 10th. Finally, BTIG Research cut shares of NxStage Medical from a “buy” rating to a “neutral” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating and nine have issued a hold rating to the stock. The company currently has an average rating of “Hold” and an average price target of $30.25.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.